Table of contents

Clinical/translational cancer immunotherapy

• Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis (30 April, 2021)

  Martin Böttcher, Heiko Bruns, Simon Völkl, Junyan Lu, Elisavet Chartomatsidou, Nikos Papakonstantinou, Kristin Mentz, Maike Büttner-Herold, Thorsten Zenz, Marco Herling, Wolfgang Huber, Paolo Ghia, Kostas Stamatopoulos, Andreas Mackensen, Dimitrios Mougiakakos
• Original research: Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies (21 April, 2021)

  Sigrid P Dubois, Milos D Miljkovic, Thomas A Fleisher, Stefania Pittaluga, Jennifer Hsu-Albert, Bonita R Bryant, Michael N Petrus, Liyanage P Perera, Jürgen R Müller, Joanna H Shih, Thomas A Waldmann, Kevin C Conlon
• Original research: Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis (21 April, 2021)

  Michael W Knitz, Thomas E Bickett, Laurel B Darragh, Ayman J Oweida, Shilpa Bhatia, Benjamin Van Court, Shiv Bhuvane, Miles Piper, Jacob Gadwa, Adam C Mueller, Diemmy Nguyen, Varuna Nangia, Douglas G Osborne, Xiyuan Bai, Sarah E Ferrara, Mary-Keara Boss, Andrew Goodspeed, Matthew A Burchill, Beth A Jirón Tamburini, Edward D Chan, Curtis R Pickering, Eric T Clambey, Sana D Karam
• Original research: Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma (20 April, 2021)

  Paul Nghiem, Shailender Bhatia, Evan J Lipson, William H Sharfman, Ragini R Kudchadkar, Andrew S Brohl, Philip A Friedlander, Adil Daud, Harriet M Kluger, Sunil A Reddy, Brian C Boulmay, Adam Riker, Melissa A Burgess, Brent A Hanks, Thomas Olencki, Kari Kendra, Candice Church, Tomoko Akaike, Nirasha Ramchurren, Michi M Shinohara, Bob Salim, Janis M Taube, Erin Jensen, Mizuho Kalabis, Steven P Fling, Blanca Homet Moreno, Elad Sharon, Martin A Cheever, Suzanne L Topalian
• Original research: Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors (13 April, 2021)

  Giovanni Fucà, Francesca Corti, Margherita Ambrosini, Rossana Intini, Massimiliano Salati, Elisabetta Fenocchio, Paolo Manca, Chiara Manai, Francesca Daniel, Alessandra Raimondi, Federica Morano, Salvatore Corallo, Michele Prisciandaro, Andrea Spallanzani, Virginia Quarà, Carmen Belli, Marta Vaiani, Giuseppe Curigliano, Chiara Cremolini, Filippo De Braud, Maria Di Bartolomeo, Vittorina Zagonel, Sara Lonardi, Filippo Pietrantonio
• Original research: Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study (13 April, 2021)

  Meghan D Lee, Harish Seethapathy, Ian A Strohbehn, Sophia H Zhao, Genevieve M Boland, Riley Fadden, Ryan Sullivan, Kerry L Reynolds, Meghan E Sise
• Original research: CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation (13 April, 2021)

  Ryan Michael Reyes, Yilun Deng, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Harshita B Gupta, Alvaro S Padron, Aravind Kancharla, Chenghao Zhang, Myrna Garcia, Anand V R Kornepati, Onur Boyman, Jose R Conejo-Garcia, Robert S Svatek, Tyler J Curiel
• Original research: Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers (13 April, 2021)

  Rivka R Colen, Christian Rolfo, Murat Ak, Mira Ayoub, Sara Ahmed, Nabil Elshafeey, Priyadarshini Mamindla, Pascal O Zinn, Chaan Ng, Raghu Vikram, Spyridon Bakas, Christine B Peterson, Jordi Rodon Ahnert, Vivek Subbiah, Daniel D Karp, Bettzy Stephen, Joud Hajjar, Aung Naing
• Original research: Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor (9 April, 2021)

  Brendan D Curti, Yoshinobu Koguchi, Rom S Leidner, Annah S Rolig, Elizabeth R Sturgill, Zhaoyu Sun, Yaping Wu, Venkatesh Rajamanickam, Brady Bernard, Ian Hilgart-Martiszus, Christopher B Fountain, George Morris, Noriko Iwamoto, Takashi Shimada, ShuChing Chang, Peter G Traber, Eliezer Zomer, J Rex Horton, Harold Shlevin, William L Redmond
• Original research: Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy (7 April, 2021)

  Alessio Cortellini, Massimo Di Maio, Olga Nigro, Alessandro Leonetti, Diego L Cortinovis, Joachim GJV Aerts, Giorgia Guaitoli, Fausto Barbieri, Raffaele Giusti, Miriam G Ferrara, Emilio Bria, Ettore D'Argento, Francesco Grossi, Erika Rijavec, Annalisa Guida, Rossana Berardi, Mariangela Torniai, Vincenzo Sforza, Carlo Genova, Francesca Mazzoni, Marina Chiara Garassino, Alessandro De Toma, Diego Signorelli, Alain Gelibter, Marco Siringo, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Luigi Della Gravara, Alessandro Inno, De Tursi Michele, Antonino Grassadonia, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Daniele Santini, Fabrizio Citarella, Marco Russano, Luca Cantini, Alessandro Tuzi, Paola Bordi, Gabriele Minuti, Lorenza Landi, Serena Ricciardi, Maria R Migliorino, Francesco Passiglia, Paolo Bironzo, Giulio Metro, Vincenzo Adamo, Alessandro Russo, Gian Paolo Spinelli, Giuseppe L Banna, Alex Friedlaender, Alfredo Addeo, Katia Cannita, Corrado Ficorella, Giampiero Porzio, David J Pinato
• Original research: Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma (5 April, 2021)

  Yang Liu, Chunmeng Wang, Xiang Li, Liang Dong, Qingming Yang, Meixia Chen, Fengxia Shi, Malcolm Brock, Miao Liu, Qian Mei, Jiejie Liu, Jing Nie, Weidong Han
• Original research: Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials (1 April, 2021)

  Zi-Xian Wang, Hao-Xiang Wu, Li Xie, Wu-Hao Lin, Fei Liang, Jin Li, Zhi-Min Yang, Rui-Hua Xu